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In 1-(2-iodobenzoyl)-4-(pyrimidin-2-yl)piperazine, C15H15IN4O, the central
piperazine ring adopts an almost perfect chair conformation with the pyrimidine
substituent in an equatorial site. The planar amide unit makes a dihedral angle
of 80.44 (7) with the phenyl ring. A combination of C—H  O and C—
H  (arene) hydrogen bonds links the molecules into a complex three-
dimensional network structure, augmented by a – stacking interaction and an
I  N halogen bond, all involving different pairs of inversion-related molecules.
Comparisons are made with the structures of a number of related compounds.
1. Chemical context
Pyrimidine derivatives are well represented amongst the range
of heterocyclic compounds that exhibit a broad spectrum of
biological activities such as analgesic and anti-inflammatory
activity (Amin et al., 2009), antibacterial (Kuyper et al., 1996),
antidepressant (Kim et al., 2010), antimicrobial and anti-
oxidant (Padmaja et al., 2009) and antiviral activities (Ibrahim
& El-Metwally, 2010). Piperazine-based compounds also
exhibit anti-cancer properties (Abdel-Jalil et al., 2005), while
the combination of pyrimidine and piperazine units is found in
buspirone, 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-aza-
spiro[4.5]decane-7,9-dione (Tollefson et al., 1991), which can
be used in the treatment of anxiety. With these considerations
in mind, we have now synthesized the title compound (I)
(Fig. 1), and we report here its molecular and supramolecular
structure. Compound (I) was prepared by reaction of 1-(2-
pyrimidyl)piperazine with 2-iodobenzoic acid in the presence
of dimethylaminopropyl)-3-ethylcarbodimide as the dehy-
drating agent.
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2. Structural commentary
Within the molecule of compound (I) (Fig. 1), the piperazine
ring adopts an almost perfect chair conformation. The ring-
puckering parameters, calculated for the atom sequence (N1,
C2, C3, N4, C5, C6) are Q = 0.557 (3) A˚,  = 1.2 (3)  and ’ =
258 (14), while for an idealized chair form the value of  is
0.0 (Boeyens, 1978). The pyrimidine substituent at the pyra-
midal atom N4 occupies an equatorial site, but the amidic unit
at atom N1 is effectively planar, and the r.m.s. deviation from
the mean plane of atoms (C2, N1, C6, C17, O17 and C11) is
only 0.027 A˚. The dihedral angle between this plane and the
aryl ring (C11–C16) is 80.44 (7). The molecules of (I) thus
exhibit no internal symmetry and so are conformationally
chiral, as confirmed by the centrosymmetric space group in
which the molecule crystallizes.
3. Supramolecular features
The supramolecular assembly of compound (I) is built from
two C—H  O hydrogen bonds, involving the aryl and pyri-
midyl atoms C16 and C45 as the donors (Table 1), and one C—
H  (arene) hydrogen bond: there is a further inter-
molecular C—H  O contact, involving atom C13, but here
the D—H  A angle is less than 140, and so this contact
cannot be regarded as structurally significant (Wood et al.,
2009). There are also present in the structure a – stacking
interaction between pairs of pyrimidine rings and an I  N
halogen bond.
The hydrogen bonds give rise to a three-dimensional
network structure of considerable complexity, but this is
readily analysed in terms of three one-dimensional sub-
structures (Ferguson et al., 1998a,b; Gregson et al., 2000). The
action of the two C—H  O hydrogen bonds in combination
links molecules related by inversion and translation into a
chain of edge-fused rings running parallel to the [001] direc-
tion (Fig. 2), in which R22(10) (Etter, 1990; Etter et al., 1990;
Bernstein et al., 1995) rings centred at (0.5, 0.5, n + 0.5)
alternate with R24(28) rings centred at (0.5, 0.5, n), where n
represents an integer in each case.
A second sub-structure can be identified in which the C—
H  (arene) hydrogen bond links molecules related by a 21
screw axis to form a chain running parallel to the [010]
direction (Fig. 3). The chains parallel to [010] and [001] each
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Table 1
Hydrogen-bond geometry (A˚, ).
# Cg1 is the centroid of the C11–C16 ring.
D—H  A D—H H  A D  A D—H  A
C16—H16  O17i 0.95 2.50 3.395 (3) 157
C45—H45  O17ii 0.95 2.57 3.508 (3) 169
C46—H46  Cg1iii 0.95 2.72 3.596 (3) 153
Symmetry codes: (i) xþ 1;yþ 1;zþ 1; (ii) x; y; zþ 1; (iii) x þ 12; yþ 12;zþ 32.
Figure 2
Part of the crystal structure of compound (I) showing the formation of a
hydrogen-bonded chain of edge-fused rings parallel to the [001] direction.
Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, the
H atoms not involved in the motif shown have been omitted. The I atoms
marked with an asterisk (*), a hash (#) or a dollar sign ($) are at the
symmetry positions (1  x, 1  y, 1  z), (x, y, 1 + z) and (1  x, 1  y,
2  z), respectively.
Figure 1
The molecular structure of compound (I) showing the atom-labelling
scheme. Displacement ellipsoids are drawn at the 50% probability level.
use only one type of hydrogen bond, but the alternating action
of the C—H  O and C—H  (arene) hydrogen bonds
involving atoms C16 and C46 as the donors (Table 1) links the
molecules into a chain of rings running parallel to the [111]
direction (Fig. 4). The combination of chains running parallel
to [010], [001] and [111] suffices to generate a continuous
three-dimensional network structure.
The formation of the hydrogen-bonded network is
augmented by two further intermolecular interactions, each of
which involves inversion related pairs of molecules. The
pyrimidine rings of the molecules at (x, y, z) and (1  x, 1  y,
2  z), which are components of the hydrogen-bonded chain
along [001], are strictly parallel with an interplanar spacing of
3.4295 (10) A˚ and a ring-centroid separation of 3.4924 (6) A˚,
thus giving rise to a – stacking interaction (Fig. 5). Finally,
we note a short intermolecular I  N contact with geometrical
parameters of I12  N41i = 3.168 (2) A˚ and C12—I12  N41i
174.83 (7) [symmetry code: (i) x, 1  y, 1  z], which can be
regarded as a halogen bond (Gilday et al., 2015; Cavallo et al.,
2016).
4. Database survey
It is of interest briefly to compare the structure of compound
(I) reported here with those of some related structures which
have been recently reported. In 2-{4-[(1,3-benzodioxol-5-
yl)methyl]piperazin-1-yl}pyrimidine (II), the molecules are
linked into sheets by a combination of C—H  (arene) and
C—H  (pyrimidine) hydrogen bonds (Wu et al., 2013).
N-(4-Chlorophenyl)-4-(pyrimidin-2-yl)piperazine-1-carbox-
amide (III) crystallizes with Z0 = 2 in space group P21/c (Li,
2011b), and the molecules are linked into chains by two
independent N—H  O hydrogen bonds: these chains, parallel
to [100], are of the C22(8) type rather than of the C(4) type as
originally reported. However, the original report overlooked
the presence of C—H  O hydrogen bonds which, in
combination with the N—H  O hydrogen bond within the
selected asymmetric unit, generates a second chain, this time
running parallel to the [010] direction (Fig. 6), so that overall
the supramolecular assembly takes the form of a sheet parallel
to (001). In the simpler analogue N-(4-chlorophenyl)-4-
methylpiperidine-1-carboxamide (IV), the assembly was
reported (Li, 2011a) as consisting of simple C(4) chains built
from N—H  O hydrogen bonds. However, the presence in
(IV) of a C—H  O hydrogen bond was overlooked, and the
two hydrogen bonds together generate a complex sheet
structure lying parallel to (100) (Fig. 7). Finally, we note also
the structures of a number of salts of the 4-(pyrimidin-2-
yl)piperazin-1-ium cation, including the chloride and nitrate
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Figure 4
Part of the crystal structure of compound (I) showing the formation of a
hydrogen-bonded chain of rings parallel to the [111] direction. Hydrogen
bonds are drawn as dashed lines and, for the sake of clarity, the H atoms
not involved in the motif shown have been omitted. The I atoms marked
with an asterisk (*), a hash (#), a dollar sign ($), an ampersand (&) or a
percent sign (%) are at the symmetry positions (1 x, 1 y, 1 z), (12  x,
1
2 + y,
3
2  z), (12 + x, 32  y, 12 + z), (12 + x, 12  y, 12 + z) and (1.5  x, 12 + y,
1
2  z) respectively.
Figure 3
Part of the crystal structure of compound (I) showing the formation of a
hydrogen-bonded chain parallel to the [010] direction. Hydrogen bonds
are drawn as dashed lines and, for the sake of clarity, the H atoms not
involved in the motif shown have been omitted. The I atoms marked with
an asterisk (*), a hash (#) or a dollar sign ($) are at the symmetry
positions (12  x, 12 + y, 32  z), (12  x, 12 + y, 32  z) and (x, 1 + y, z),
respectively.
(Yamuna et al., 2014a), the hydrogenfumarate (Yamuna et al.,
2014b) and the butanoate (Yamuna et al., 2014c).
5. Synthesis and crystallization
1-(2-Pyrimidyl)piperazine was purchased from Sigma–
Aldrich. For the synthesis of compound (I), 1-(3-dimethyl-
aminopropyl)-3-ethylcarbodimide (52 mg, 0.6 mmol), 1-hy-
droxybenzotriazole (81 mg, 0.6 mmol) and triethylamine
(0.5 ml, 1.8 mmol) were added to a solution of 2-iodobenzoic
acid (0.6 mmol) in N,N-dimethylformamide (5 ml) and the
resulting mixture stirred for 20 mins at 273 K. A solution of
1-(2-pyrimidyl)piperazine (100 mg, 0.6 mmol) in N,N-di-
methylformamide (5 ml) was then added and stirring was
continued overnight at ambient temperature. The reaction was
confirmed to be complete using thin-layer chromatography,
and the mixture was then quenched with water (10 ml) and
extracted with ethyl acetate (20 ml). The organic layer was
separated and washed successively with an aqueous hydro-
chloric acid solution (1 mol dm3), a saturated solution of
sodium hydrogencarbonate and then with brine. The organic
phase was dried over anhydrous sodium sulfate and the
solvent was removed under reduced pressure. Crystals
suitable for single-crystal X-ray diffraction were grown by
slow evaporation, at ambient temperature and in the presence
of air, of a solution in methanol; m. p. 450–452 K.
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Figure 6
Part of the crystal structure of compound (III) showing the formation of a
hydrogen-bonded chain parallel to [010]. The original atomic coordinates
(Li, 2011b) have been used and, for the sake of clarity, the H atoms not
involved in the motif shown have been omitted.
Figure 7
Part of the crystal structure of compound (IV) showing the formation of a
hydrogen-bonded sheet parallel to (100). The original atomic coordinates
(Li, 2011a) have been used and, for the sake of clarity, the H atoms not
involved in the motif shown have been omitted.
Figure 5
Part of the crystal structure of compound (I) showing the – stacking
interaction between adjacent pyrimidine rings. For the sake of clarity, the
unit-cell outline and the H atoms have been omitted. The I atom marked
with an asterisk (*) is at the symmetry position (1  x, 1  y, 2  z).
6. Refinement
Crystal data, data collection and structure refinement details
are summarized in Table 2. All H atoms were located in
difference maps, and they were subsequently treated as riding
atoms in geometrically idealized positions with C—H
distances of 0.95 A˚ (aromatic) or 0.99 A˚ (CH2), and with
Uiso(H) = 1.2Ueq(C).
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Table 2
Experimental details.
Crystal data
Chemical formula C15H15IN4O
Mr 394.21
Crystal system, space group Monoclinic, P21/n
Temperature (K) 173
a, b, c (A˚) 9.6417 (17), 13.604 (2), 12.174 (2)
 () 105.155 (2)
V (A˚3) 1541.3 (4)
Z 4
Radiation type Mo K
 (mm1) 2.08
Crystal size (mm) 0.67  0.56  0.16
Data collection
Diffractometer Bruker APEXII CCD
Absorption correction Multi-scan (SADABS; Bruker,
2015)
Tmin, Tmax 0.345, 0.717
No. of measured, independent and
observed [I > 2(I)] reflections
8152, 3452, 3188
Rint 0.067
(sin /)max (A˚
1) 0.652
Refinement
R[F 2 > 2(F 2)], wR(F 2), S 0.028, 0.075, 1.05
No. of reflections 3452
No. of parameters 190
H-atom treatment H-atom parameters constrained
	max, 	min (e A˚
3) 0.96, 0.74
Computer programs: APEX2 (Bruker, 2004), SAINT (Bruker, 2015), SHELXT
(Sheldrick, 2015a), SHELXL2014 (Sheldrick, 2015b) and PLATON (Spek, 2009).
supporting information
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Computing details 
Data collection: APEX2 (Bruker, 2004); cell refinement: SAINT (Bruker, 2015); data reduction: SAINT (Bruker, 2015); 
program(s) used to solve structure: SHELXT (Sheldrick, 2015a); program(s) used to refine structure: SHELXL2014 
(Sheldrick, 2015b); molecular graphics: PLATON (Spek, 2009); software used to prepare material for publication: 
SHELXL2014 (Sheldrick, 2015b) and PLATON (Spek, 2009).
1-(2-Iodobenzoyl)-4-(pyrimidin-2-yl)piperazine 
Crystal data 
C15H15IN4O
Mr = 394.21
Monoclinic, P21/n
a = 9.6417 (17) Å
b = 13.604 (2) Å
c = 12.174 (2) Å
β = 105.155 (2)°
V = 1541.3 (4) Å3
Z = 4
F(000) = 776
Dx = 1.699 Mg m−3
Mo Kα radiation, λ = 0.71073 Å
Cell parameters from 3152 reflections
θ = 2.3–27.6°
µ = 2.08 mm−1
T = 173 K
Plate, colour
0.67 × 0.56 × 0.16 mm
Data collection 
Bruker APEXII CCD 
diffractometer
Radiation source: fine focus sealed tube
Graphite monochromator
Detector resolution: 0.3333 pixels mm-1
φ and ω scans
Absorption correction: multi-scan 
(SADABS; Bruker, 2015)
Tmin = 0.345, Tmax = 0.717
8152 measured reflections
3452 independent reflections
3188 reflections with I > 2σ(I)
Rint = 0.067
θmax = 27.6°, θmin = 2.3°
h = −12→10
k = −17→16
l = −15→15
Refinement 
Refinement on F2
Least-squares matrix: full
R[F2 > 2σ(F2)] = 0.028
wR(F2) = 0.075
S = 1.05
3452 reflections
190 parameters
0 restraints
Hydrogen site location: inferred from 
neighbouring sites
supporting information
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H-atom parameters constrained
w = 1/[σ2(Fo2) + (0.0235P)2 + 0.7279P] 
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max = 0.001
Δρmax = 0.96 e Å−3
Δρmin = −0.74 e Å−3
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq
N1 0.2388 (2) 0.44984 (14) 0.52539 (16) 0.0253 (4)
C2 0.2263 (3) 0.36447 (15) 0.5950 (2) 0.0282 (6)
H2A 0.2567 0.3046 0.5613 0.034*
H2B 0.1248 0.3559 0.5964 0.034*
C3 0.3195 (3) 0.37777 (17) 0.7159 (2) 0.0290 (6)
H3A 0.3033 0.3225 0.7640 0.035*
H3B 0.4222 0.3777 0.7159 0.035*
N4 0.2839 (2) 0.47043 (14) 0.76229 (16) 0.0260 (4)
C5 0.2977 (3) 0.55610 (16) 0.69257 (18) 0.0247 (5)
H5A 0.3991 0.5637 0.6904 0.030*
H5B 0.2689 0.6163 0.7265 0.030*
C6 0.2028 (3) 0.54263 (17) 0.57233 (19) 0.0273 (5)
H6A 0.1005 0.5421 0.5735 0.033*
H6B 0.2174 0.5980 0.5239 0.033*
C17 0.2929 (3) 0.45026 (16) 0.43404 (17) 0.0211 (4)
O17 0.3118 (2) 0.52552 (12) 0.38448 (14) 0.0334 (4)
C11 0.3328 (3) 0.35268 (15) 0.39109 (19) 0.0195 (5)
C12 0.2434 (2) 0.30692 (15) 0.29625 (17) 0.0191 (4)
I12 0.03709 (2) 0.36186 (2) 0.21850 (2) 0.02547 (8)
C13 0.2883 (3) 0.22226 (16) 0.25098 (19) 0.0257 (5)
H13 0.2268 0.1909 0.1867 0.031*
C14 0.4237 (3) 0.18428 (17) 0.3008 (2) 0.0327 (6)
H14 0.4553 0.1269 0.2699 0.039*
C15 0.5130 (3) 0.22889 (19) 0.3947 (2) 0.0346 (6)
H15 0.6054 0.2021 0.4284 0.042*
C16 0.4677 (3) 0.31314 (18) 0.4401 (2) 0.0279 (5)
H16 0.5293 0.3438 0.5048 0.033*
N41 0.2769 (2) 0.57158 (16) 0.91400 (17) 0.0301 (5)
C42 0.3025 (2) 0.48172 (17) 0.87784 (18) 0.0221 (4)
N43 0.3414 (2) 0.40176 (15) 0.94349 (17) 0.0280 (4)
C44 0.3528 (3) 0.4150 (2) 1.0545 (2) 0.0328 (6)
H44 0.3790 0.3601 1.1039 0.039*
C45 0.3288 (3) 0.5033 (2) 1.1012 (2) 0.0318 (6)
H45 0.3381 0.5108 1.1804 0.038*
C46 0.2902 (3) 0.5804 (2) 1.0258 (2) 0.0338 (6)
H46 0.2721 0.6427 1.0546 0.041*
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Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
N1 0.0418 (12) 0.0171 (8) 0.0180 (9) 0.0026 (9) 0.0095 (8) −0.0025 (7)
C2 0.0455 (17) 0.0190 (11) 0.0247 (13) −0.0072 (10) 0.0172 (12) −0.0029 (8)
C3 0.0496 (17) 0.0193 (10) 0.0211 (12) 0.0030 (12) 0.0149 (11) 0.0016 (9)
N4 0.0421 (12) 0.0213 (9) 0.0161 (9) 0.0009 (10) 0.0101 (8) −0.0012 (7)
C5 0.0377 (13) 0.0191 (10) 0.0182 (11) 0.0013 (11) 0.0088 (9) −0.0022 (8)
C6 0.0411 (14) 0.0223 (10) 0.0181 (10) 0.0059 (11) 0.0069 (10) −0.0043 (9)
C17 0.0304 (11) 0.0176 (9) 0.0124 (9) 0.0005 (10) 0.0007 (8) −0.0020 (8)
O17 0.0646 (13) 0.0173 (7) 0.0196 (8) 0.0013 (9) 0.0133 (8) 0.0014 (6)
C11 0.0302 (12) 0.0145 (9) 0.0150 (10) −0.0006 (9) 0.0079 (9) 0.0014 (7)
C12 0.0263 (11) 0.0174 (9) 0.0153 (9) −0.0017 (9) 0.0084 (8) 0.0003 (8)
I12 0.02670 (12) 0.02407 (11) 0.02409 (11) −0.00088 (5) 0.00387 (8) −0.00347 (5)
C13 0.0421 (14) 0.0163 (10) 0.0218 (11) −0.0010 (11) 0.0141 (10) −0.0016 (8)
C14 0.0491 (16) 0.0192 (11) 0.0374 (14) 0.0070 (12) 0.0250 (12) 0.0005 (10)
C15 0.0345 (13) 0.0304 (13) 0.0408 (14) 0.0108 (13) 0.0132 (11) 0.0083 (11)
C16 0.0313 (12) 0.0261 (11) 0.0238 (11) 0.0009 (11) 0.0031 (9) 0.0020 (9)
N41 0.0378 (12) 0.0343 (11) 0.0186 (10) 0.0082 (10) 0.0081 (8) −0.0043 (8)
C42 0.0214 (10) 0.0286 (11) 0.0174 (10) −0.0028 (10) 0.0070 (8) −0.0009 (9)
N43 0.0368 (12) 0.0279 (10) 0.0214 (10) −0.0055 (10) 0.0115 (8) 0.0019 (8)
C44 0.0384 (14) 0.0388 (14) 0.0224 (12) −0.0092 (13) 0.0099 (10) 0.0063 (10)
C45 0.0351 (13) 0.0452 (14) 0.0169 (11) −0.0073 (13) 0.0098 (9) −0.0023 (10)
C46 0.0400 (14) 0.0428 (14) 0.0199 (12) 0.0034 (13) 0.0102 (10) −0.0060 (11)
Geometric parameters (Å, º) 
N1—C17 1.346 (3) C11—C12 1.394 (3)
N1—C2 1.461 (3) C12—C13 1.393 (3)
N1—C6 1.464 (3) C12—I12 2.104 (2)
C2—C3 1.521 (4) C13—C14 1.388 (4)
C2—H2A 0.9900 C13—H13 0.9500
C2—H2B 0.9900 C14—C15 1.379 (4)
C3—N4 1.459 (3) C14—H14 0.9500
C3—H3A 0.9900 C15—C16 1.391 (3)
C3—H3B 0.9900 C15—H15 0.9500
N4—C42 1.379 (3) C16—H16 0.9500
N4—C5 1.468 (3) N41—C46 1.339 (3)
C5—C6 1.521 (3) N41—C42 1.344 (3)
C5—H5A 0.9900 C42—N43 1.344 (3)
C5—H5B 0.9900 N43—C44 1.340 (3)
C6—H6A 0.9900 C44—C45 1.375 (4)
C6—H6B 0.9900 C44—H44 0.9500
C17—O17 1.226 (3) C45—C46 1.380 (4)
C17—C11 1.513 (3) C45—H45 0.9500
C11—C16 1.390 (3) C46—H46 0.9500
C17—N1—C2 126.25 (18) C16—C11—C12 119.3 (2)
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C17—N1—C6 120.10 (19) C16—C11—C17 119.1 (2)
C2—N1—C6 113.23 (17) C12—C11—C17 121.3 (2)
N1—C2—C3 110.4 (2) C13—C12—C11 120.5 (2)
N1—C2—H2A 109.6 C13—C12—I12 118.05 (18)
C3—C2—H2A 109.6 C11—C12—I12 121.41 (16)
N1—C2—H2B 109.6 C14—C13—C12 119.2 (2)
C3—C2—H2B 109.6 C14—C13—H13 120.4
H2A—C2—H2B 108.1 C12—C13—H13 120.4
N4—C3—C2 109.7 (2) C15—C14—C13 120.7 (2)
N4—C3—H3A 109.7 C15—C14—H14 119.6
C2—C3—H3A 109.7 C13—C14—H14 119.6
N4—C3—H3B 109.7 C14—C15—C16 119.9 (2)
C2—C3—H3B 109.7 C14—C15—H15 120.0
H3A—C3—H3B 108.2 C16—C15—H15 120.0
C42—N4—C3 120.7 (2) C11—C16—C15 120.3 (2)
C42—N4—C5 119.60 (18) C11—C16—H16 119.8
C3—N4—C5 113.33 (17) C15—C16—H16 119.8
N4—C5—C6 109.75 (19) C46—N41—C42 116.0 (2)
N4—C5—H5A 109.7 N41—C42—N43 126.0 (2)
C6—C5—H5A 109.7 N41—C42—N4 116.7 (2)
N4—C5—H5B 109.7 N43—C42—N4 117.3 (2)
C6—C5—H5B 109.7 C44—N43—C42 115.3 (2)
H5A—C5—H5B 108.2 N43—C44—C45 123.8 (2)
N1—C6—C5 109.6 (2) N43—C44—H44 118.1
N1—C6—H6A 109.8 C45—C44—H44 118.1
C5—C6—H6A 109.8 C44—C45—C46 115.8 (2)
N1—C6—H6B 109.8 C44—C45—H45 122.1
C5—C6—H6B 109.8 C46—C45—H45 122.1
H6A—C6—H6B 108.2 N41—C46—C45 123.1 (2)
O17—C17—N1 123.3 (2) N41—C46—H46 118.5
O17—C17—C11 118.59 (19) C45—C46—H46 118.5
N1—C17—C11 118.07 (19)
C17—N1—C2—C3 116.2 (3) C17—C11—C12—I12 −7.2 (3)
C6—N1—C2—C3 −56.4 (3) C11—C12—C13—C14 −0.6 (3)
N1—C2—C3—N4 54.1 (3) I12—C12—C13—C14 −179.83 (16)
C2—C3—N4—C42 151.8 (2) C12—C13—C14—C15 0.6 (3)
C2—C3—N4—C5 −56.4 (3) C13—C14—C15—C16 −0.3 (4)
C42—N4—C5—C6 −150.6 (2) C12—C11—C16—C15 0.1 (3)
C3—N4—C5—C6 57.3 (3) C17—C11—C16—C15 −173.4 (2)
C17—N1—C6—C5 −116.3 (2) C14—C15—C16—C11 −0.1 (4)
C2—N1—C6—C5 56.8 (3) C46—N41—C42—N43 −1.0 (4)
N4—C5—C6—N1 −55.3 (2) C46—N41—C42—N4 177.6 (2)
C2—N1—C17—O17 −173.7 (3) C3—N4—C42—N41 175.3 (2)
C6—N1—C17—O17 −1.6 (4) C5—N4—C42—N41 25.3 (3)
C2—N1—C17—C11 6.0 (4) C3—N4—C42—N43 −6.0 (3)
C6—N1—C17—C11 178.1 (2) C5—N4—C42—N43 −156.1 (2)
O17—C17—C11—C16 94.4 (3) N41—C42—N43—C44 1.1 (4)
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N1—C17—C11—C16 −85.3 (3) N4—C42—N43—C44 −177.5 (2)
O17—C17—C11—C12 −78.9 (3) C42—N43—C44—C45 −0.7 (4)
N1—C17—C11—C12 101.4 (3) N43—C44—C45—C46 0.4 (4)
C16—C11—C12—C13 0.2 (3) C42—N41—C46—C45 0.5 (4)
C17—C11—C12—C13 173.52 (19) C44—C45—C46—N41 −0.3 (4)
C16—C11—C12—I12 179.44 (16)
Hydrogen-bond geometry (Å, º) 
# Cg1 is the centroid of the C11–C16 ring.
D—H···A D—H H···A D···A D—H···A
C13—H13···O17i 0.95 2.40 3.160 (3) 136
C16—H16···O17ii 0.95 2.50 3.395 (3) 157
C45—H45···O17iii 0.95 2.57 3.508 (3) 169
C46—H46···Cg1iv 0.95 2.72 3.596 (3) 153
Symmetry codes: (i) −x+1/2, y−1/2, −z+1/2; (ii) −x+1, −y+1, −z+1; (iii) x, y, z+1; (iv) −x+1/2, y+1/2, −z+3/2.
